Broadcom named strategic vendor for Walmart virtualization solutions
GE HealthCare (NASDAQ:GEHC) Technologies Inc., a prominent player in the Healthcare Equipment & Supplies industry with a market capitalization of $32.8 billion, has announced the issuance of $1.5 billion in senior unsecured notes, according to a filing with the Securities and Exchange Commission (SEC) on Monday. According to InvestingPro data, the company maintains a robust EBITDA of $3.66 billion over the last twelve months. The company, operating under the industrial classification of X-ray apparatus and related irradiation apparatus, has issued $650 million in 4.800% senior notes due January 15, 2031, and $850 million in 5.500% senior notes due June 15, 2035. This debt issuance comes as the company maintains a debt-to-equity ratio of 1.0 and receives a "GOOD" financial health score from InvestingPro’s comprehensive analysis system.
The notes were issued under the terms of an indenture dated November 22, 2022, and are further detailed in a third supplemental indenture as of Monday. These notes are senior unsecured obligations and will rank equally with the company’s other senior unsecured debt. Interest on the 2031 notes is payable semi-annually on January 15 and July 15, beginning in 2026, while the 2035 notes will pay interest on June 15 and December 15, with the first payment due on December 15, 2025.
The company, with its principal executive offices located in Chicago, Illinois, has listed its common stock on The Nasdaq Stock Market LLC under the trading symbol GEHC. This issuance aligns with GE HealthCare Technologies Inc.’s effective shelf registration statement on Form S-3 (File No. 333-280584). The Bank of New York Mellon (NYSE:BK) serves as the trustee for the issued notes.
The SEC filing also includes references to the exhibits related to the notes, including the base indenture, the supplemental indenture, and forms of the 2031 and 2035 notes. Additionally, opinions and consents from Gibson, Dunn & Crutcher LLP are listed as exhibits in the filing.
This financial move by GE HealthCare Technologies Inc. reflects its ongoing capital management strategy, and the details provided in the SEC filing offer transparency for investors and stakeholders. The information is based on a press release statement. InvestingPro analysis suggests the stock is currently trading below its Fair Value, with additional insights available through their comprehensive Pro Research Report, which offers deep-dive analysis of over 1,400 US stocks.
In other recent news, GE HealthCare Technologies Inc. reported a strong financial performance for the first quarter of 2025. The company achieved a revenue of $4.8 billion, marking a 4% organic growth year-over-year, and an adjusted earnings per share (EPS) increase of 12% to $1.01. Additionally, GE HealthCare recorded a record backlog of $20.6 billion, reflecting robust demand in the U.S. and European markets. The company’s stockholder meeting saw the re-election of 10 directors and the approval of executive compensation, while a proposal on termination pay arrangements was rejected. Deloitte & Touche LLP was ratified as the independent auditor for the fiscal year ending December 31, 2025. GE HealthCare also launched several innovative products, including a new PET imaging agent, which is part of its strategic initiatives to expand market share. The company projects organic revenue growth between 2% and 3% for the full year 2025, with an anticipated adjusted EPS in the range of $3.90 to $4.10. Lastly, the company is actively working on mitigating tariff impacts, with plans to reduce these effects further in 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.